Relationship between brain atrophy and disability: An 8-year follow-up study of multiple sclerosis patients

Multiple Sclerosis

Volumn 6, Issue 6, 2000, Pages 373-377

  Fisher, E ^a   Rudick, R A ^a   Cutter, G ^b   Baier, M ^b   Miller, D ^a   Weinstock Guttman, B ^c   Mass, M K ^d   Dougherty, D S ^e   Simonian, N A ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c BUFFALO GENERAL HOSPITAL   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f BIOGEN   (United States)

Author keywords

Brain atrophy; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON;

ARTICLE; BRAIN ATROPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NEUROMUSCULAR FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENCHYMA; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION;

ADJUVANTS, IMMUNOLOGIC; ATROPHY; BRAIN; CLINICAL TRIALS, PHASE III; DISABILITY EVALUATION; ECHO-PLANAR IMAGING; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MULTICENTER STUDIES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS;

EID: 0034490261     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245800701566331     Document Type: Article

References (18)

1. A longitudinal study of brain atrophy in relapsing multiple sclerosis
2. Progressive cerebral atrophy in multiple sclerosis: A serial MRI study
3. Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment
4. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis
5. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
6. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment
7. Axonal transection in the lesions of multiple sclerosis
8. Imaging axonal damage of normal-appearing white matter in multiple sclerosis
9. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy
10. Neurodegeneration in multiple sclerosis: Relationship to neurological disability
11. A phase III trial of intramuscular recombinant interferon beta as a treatment for exacerbating-remitting multiple sclerosis: Design and conduct of study and baseline characteristics of patients
12. Knowledge-based 3D segmentation of MR images for quantitative MS lesion tracking
13. Recommendations from the Clinical Outcomes Assessment Task Force of the National Multiple Sclerosis Society
14. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression
15. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis
16. Quantitative volumetric analysis of brain magnetic resonance imaging from patients with multiple sclerosis
17. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: Longitudinal quantitative analysis
18. Variability of brain atrophy in multiple sclerosis